Miastina

Rosuvastatin, the active ingredient in Miastina, is a HMG‑CoA reductase inhibitor presented as an oral tablet for systemic use. It lowers elevated cholesterol and triglyceride levels and is indicated for patients with hypercholesterolemia, mixed dyslipidemia, and for cardiovascular risk reduction.

GNH USA supplies Miastina as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for formulary needs. Customers benefit from comprehensive regulatory support and flexible shipment options tailored to regional requirements.

Rosuvastatin is used to manage lipid disorders and reduce cardiovascular risk. - Hypercholesterolemia: lowers LDL‑cholesterol and total cholesterol levels. - Mixed dyslipidemia: improves the overall lipid profile by reducing triglycerides and raising HDL‑cholesterol. - Primary prevention of cardiovascular events: decreases the incidence of heart attack and stroke in high‑risk patients without prior events. - Secondary prevention of cardiovascular events: reduces recurrence of cardiovascular events in patients with established disease.

Rosuvastatin may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity. - Myalgia: muscle aches without weakness. - Nausea: occasional gastrointestinal upset. - Abdominal pain: mild discomfort. - Dizziness: transient episodes. - Elevated liver enzymes: mild, reversible increases.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown with possible renal impairment. - Hepatotoxicity: significant liver injury indicated by marked enzyme elevation. - Myocardial infarction: rare occurrence of heart attack. - Acute renal failure: sudden loss of kidney function. - Severe allergic reactions: including angioedema and anaphylaxis.

When prescribing rosuvastatin, clinicians should consider several safety precautions to minimize risk. - Pregnancy contraindication: rosuvastatin is classified Category X and must not be used during pregnancy. - Breastfeeding: avoid use as it may pass into milk and affect the infant. - Liver disease: assess hepatic function before initiating therapy. - Renal impairment: dose adjustment may be required in patients with reduced kidney function. - Drug interactions: review concomitant medications that affect statin metabolism. - Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture and light.

Rosuvastatin can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Cyclosporine: may increase rosuvastatin plasma concentrations, raising risk of myopathy. - Gemfibrozil: combined use can significantly raise statin levels and risk of rhabdomyolysis. - Strong CYP2C9 inhibitors (e.g., fluconazole): can elevate rosuvastatin exposure.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: may reduce rosuvastatin absorption. - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Niacin: can increase risk of muscle toxicity when used together.